Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Deepwise Completes C Round for China AI Medical Imaging Diagnostics

publication date: Jun 12, 2019

Deepwise, a Beijing-Hangzhou AI-based medical imaging diagnostics company, has completed a Series C round of undisclosed size. In three previous fundings, Deepwise raised $43 million. Formerly known as the AI Lab Project of Peking University, Deepwise was spun out of PU in 2017. The company's products are now used in 200 China hospitals. Deepwise said its success is due in part to its academic and scientific network. The C round was led by Sunshine Insurance Group, Changfazhan, SRHC and the Sunland Fund. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital